Prospera Energy (PEI.V)’s big corporate evolution: From incompetence to dishonesty
Brera Holdings (BREA.Q) pioneering pubco sports investment model, but is it a win?
“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Cybin (CYBN.NE) announced that the Institutional Review Board (IRB) has granted them approval to begin the study of its sublingual psilocybin formulation, CYB001, in a Phase II clinical trial for patients suffering from Major Depressive Disorder (MDD). Read full article here: https://equity.guru/2021/05/18/cybin-cybn-ne-receives-approval-from-irb-for-cyb001-phase-ii-clinical-trial/
